Table. Clinical trials of EGFR-TKI in EGFR mutated NSCLC
Authors Numbers of patients Groups mOS(month) P value mPFS(month) P value ORR P value
MokTS [11] 261 Gefitinib 10 P<0.001 71.20% P<0.001
Carboplatin + paclitaxel 7 47.30%
Maemondo M [12] 230 Gefitinib 30.5 P<0.001 10.8 P<0.001 73.70% P<0.001
Carboplatin + paclitaxel 23.6 5.4 30.70%
Sun JM [14] 33 Gefitinib 15.7 P<0.01 87.50% P<0.01
Pemetrexed 2.9 38.90%
Mitsudomi T [15] 172 Gefitinib 9.2 P<0.0001 62.10% P<0.0001
Docetaxel 6.3 32.20%
Wu YL [16] 217 Erlotinib 26.3 P=0.607 11 P<0.0001 62.70% P<0.0001
Gemcitabine + cisplatin 25.5 5.5 33.60%
Zhou C [17, 18] 154 Erlotinib 22.8 P=0.2663 13.1 P<0.0001 83% P<0.0001
Standard chemotherapy 27.2 4.6 36%
Rosell R [21] 174 Erlotinib 19.3 P=0.87 9.7 P<0.0001
Standard chemotherapy 19.5 5.2
Wu YL [23] 364 Afatinib 11 P<0.0001 66.90% P<0.0001
Cisplatin + gemcitabine 5.6 23%
Sequist LV [24] 345 Afatinib 11.1 P=0.001 56% P=0.001
Cisplatin + pemetrexed 6.9 23%
Wu YL& Mok TS [26, 27] 452 Dacomitinib 34.1 P=0.0438 14.7 P<0.0001 75% P=0.2224
Gefitinib 26.8 9.2 70%
Soria JC& Ramalingam SS [28, 29] 556 Osimertinib 38.6 P=0.046 18.9 P<0.001 80% P=0.24
Gefitinib 31.8 10.2 76%
Mok TS [30] 419 Osimertinib 10.1 P<0.001 71% P<0.001
Pemetrexed + Carboplatin / cisplatin 4.4 31%